XOMA Royalty Corporation (NASDAQ:XOMA) Given Average Rating of “Hold” by Analysts

XOMA Royalty Corporation (NASDAQ:XOMA) has been assigned a consensus recommendation of “Hold” from the six analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and three have assigned a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $61.60.

A number of research firms recently weighed in on XOMA. Benchmark reaffirmed a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Weiss Ratings reissued a “hold (c-)” rating on shares of XOMA Royalty in a research note on Monday, December 29th. Stifel Nicolaus set a $50.00 price objective on XOMA Royalty in a report on Friday, December 12th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a research report on Tuesday, February 24th. Finally, Zacks Research cut XOMA Royalty from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 10th.

XOMA Royalty Trading Down 1.2%

XOMA opened at $30.17 on Friday. XOMA Royalty has a 1-year low of $18.35 and a 1-year high of $39.92. The company has a current ratio of 3.37, a quick ratio of 3.37 and a debt-to-equity ratio of 1.15. The company has a market cap of $359.20 million, a P/E ratio of 20.66 and a beta of 0.86. The company has a fifty day moving average price of $26.32 and a two-hundred day moving average price of $30.28.

XOMA Royalty (NASDAQ:XOMA) last released its quarterly earnings data on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.16. The company had revenue of $13.76 million for the quarter, compared to analysts’ expectations of $11.13 million. XOMA Royalty had a net margin of 45.75% and a return on equity of 10.32%. Analysts predict that XOMA Royalty will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock worth $112,000 after purchasing an additional 543 shares in the last quarter. Russell Investments Group Ltd. lifted its position in shares of XOMA Royalty by 3,436.4% during the 3rd quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares in the last quarter. State of Alaska Department of Revenue bought a new position in shares of XOMA Royalty during the 4th quarter worth approximately $27,000. Dimensional Fund Advisors LP boosted its stake in shares of XOMA Royalty by 4.5% in the 3rd quarter. Dimensional Fund Advisors LP now owns 29,190 shares of the biotechnology company’s stock worth $1,124,000 after buying an additional 1,269 shares during the last quarter. Finally, Tower Research Capital LLC TRC boosted its stake in shares of XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,523 shares during the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.